MaaT Pharma (ENXTPA:MAAT) - Share price, News & Analysis

MAAT fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	2/6
Past Performance	0/6
Financial Health	3/6
Dividends	0/6

MAAT Stock Overview

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors.

Rewards

Revenue is forecast to grow 31.03% per year

Risk Analysis

Earnings have declined by 18.3% per year over past 5 years

Does not have meaningful revenue (€972K)

MaaT Pharma Competitors

Price History & Performance

Summary of all time highs, changes and price drops for MaaT Pharma
Historical stock prices
Current Share Price	€12.00
52 Week High	€14.40
52 Week Low	€9.50
Beta	0
1 Month Change	-5.51%
3 Month Change	-2.83%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-13.98%

Shareholder Returns

	MAAT	FR Biotechs	FR Market
7D	8.1%	-0.4%	3.7%
1Y	n/a	-39.4%	-3.7%

Return vs Industry: Insufficient data to determine how MAAT performed against the French Biotechs industry.

Return vs Market: Insufficient data to determine how MAAT performed against the French Market.

Price Volatility

Is MAAT's price volatile compared to industry and market?
MAAT volatility
MAAT Average Weekly Movement	6.1%
Biotechs Industry Average Movement	8.8%
Market Average Movement	5.9%
10% most volatile stocks in FR Market	9.8%
10% least volatile stocks in FR Market	3.4%

Stable Share Price: MAAT is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: MAAT's weekly volatility (6%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2014	37	Herve Affagard	https://www.maatpharma.com

MaaT Pharma SA, a clinical stage company, engages in the research and development of microbiome biotherapies for the treatment of solid cancer tumors. Its products pipeline includes MaaT013 that has completed phase 2 clinical trials for the treatment of acute graft versus host diseases, as well as in preclinical trials to treat melanoma; MaaT033, which is in phase 1b clinical trials for the improvement of survival in patients with acute myeloid leukemia or other liquid tumors receiving allogeneic hematopoietic stem cell transplantation; and MaaT03X for the treatment of solid tumors. The company was incorporated in 2014 and is headquartered in Lyon, France.

MaaT Pharma Fundamentals Summary

How do MaaT Pharma's earnings and revenue compare to its market cap?
MAAT fundamental statistics
Market Cap	€118.67m
Earnings (TTM)	-€9.02m
Revenue (TTM)	€972.00k

122.1x

P/S Ratio

-13.2x

P/E Ratio

Is MAAT overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report
MAAT income statement (TTM)
Revenue	€972.00k
Cost of Revenue	€166.00k
Gross Profit	€806.00k
Other Expenses	€9.83m
Earnings	-€9.02m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

Sep 29, 2022

Earnings per share (EPS)	-0.91
Gross Margin	82.92%
Net Profit Margin	-927.88%
Debt/Equity Ratio	48.1%

How did MAAT perform over the long term?

See historical performance and comparison

Valuation

Is MaaT Pharma undervalued compared to its fair value and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry

9.65x

Price to Book (PB) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate MAAT's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate MAAT's fair value for valuation analysis.

Price To Earnings Ratio

PE vs Industry: MAAT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the European Biotechs industry average.

PE vs Market: MAAT is unprofitable, so we can't compare its Price-To-Earnings Ratio to the French market.

Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate MAAT's PEG Ratio to determine if it is good value.

Price to Book Ratio

PB vs Industry: MAAT is overvalued based on its Price-To-Book Ratio (9.6x) compared to the FR Biotechs industry average (2.8x).

Future Growth

How is MaaT Pharma forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

2/6

Future Growth Score 2/6

Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE

31.0%

Forecasted annual revenue growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if MAAT's forecast earnings growth is above the savings rate (0.3%).

Earnings vs Market: Insufficient data to determine if MAAT's earnings are forecast to grow faster than the French market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: MAAT's revenue (31% per year) is forecast to grow faster than the French market (5.8% per year).

High Growth Revenue: MAAT's revenue (31% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MAAT's Return on Equity is forecast to be high in 3 years time

Past Performance

How has MaaT Pharma performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE

-18.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MAAT is currently unprofitable.

Growing Profit Margin: MAAT is currently unprofitable.

Past Earnings Growth Analysis

Earnings Trend: MAAT is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.

Accelerating Growth: Unable to compare MAAT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: MAAT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).

Return on Equity

High ROE: MAAT has a negative Return on Equity (-73.33%), as it is currently unprofitable.

Financial Health

How is MaaT Pharma's financial position?

Financial Health Score

3/6

Financial Health Score 3/6

Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: MAAT's short term assets (€19.7M) exceed its short term liabilities (€4.4M).

Long Term Liabilities: MAAT's short term assets (€19.7M) exceed its long term liabilities (€5.2M).

Debt to Equity History and Analysis

Debt Level: MAAT has more cash than its total debt.

Reducing Debt: Insufficient data to determine if MAAT's debt to equity ratio has reduced over the past 5 years.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Insufficient data to determine if MAAT has enough cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if MAAT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.

Dividend

What is MaaT Pharma current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate MAAT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate MAAT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if MAAT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if MAAT's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as MAAT has not reported any payouts.

Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.0yrs

Average management tenure

CEO

Herve Affagard (46 yo)

no data

Tenure

Mr. Herve Affagard is CEO and Co-Founder at MaaT Pharma SA. He has served as a Director at MaaT Pharma SA since 2014.

Leadership Team

Experienced Management: MAAT's management team is considered experienced (2 years average tenure).

Board Members

Experienced Board: MAAT's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.

Ownership

Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: MAAT only recently listed within the past 12 months.

Data	Last Updated (UTC time)
Company Analysis	2022/05/28 00:00
End of Day Share Price	2022/05/27 00:00
Earnings	2021/12/31
Annual Earnings	2021/12/31